Page 37 - ITP_Guide-Final

�
ื
ั
แนวทางเวชปฏิิบััติิสำำาหรัับัการัวินิจฉัยและรัักษาโรัคเกล็ดเลอดติำ�าจากภููมิิค้มิกันในเด็ก 16
Thromb Hemost 1977; 3:175.
21. lilleyman Js. Management of childhood idiopathic thrombocytopenic pur-

pura. Br J Haematol 1999; 105:871.
22. Kurtzberg J, stockman Ja 3rd. Idiopathic autoimmune thrombocytopenic
purpura. adv Pediatr 1994;41: 111.
23. wood JH, Partrick Da, Hays T, Ziegler MM. Predicting response to sple-
nectomy in children with immune thrombocytopenic purpura. J Pediatr surg
2010;45:140.
24. Katkhouda n, Mavor e. laparoscopic splenectomy. surg Clin north am
2000;80:1285.
25. wang J, wiley JM, luddy R, greenberg J, Feuerstein Ma, Bussel JB.
Chronic immune thrombocytopenic purpura in children: assessment of ritux-
imab treatment. J Pediatr 2005;146:217.
26. Kim JJ, Thrasher aJ, Jones aM, Davies eg, Cale CM. Rituximab for the

treatment of autoimmune cytopenias in children with immune deficiency. Br
J Haematol 2007;138:94.
27. Parodi e, nobili B, Perrotta s, Rosaria Matarese sM, Russo g, licciardello
M, et al. Rituximab (anti-CD20 monoclonal antibody) in children with chron-
ic refractory symptomatic immune thrombocytopenic purpura: efficacy and
safety of treatment. Int J Hematol 2006; 84:48.
28. Parodi e, Rivetti e, amendola g, Bisogno g, Calabrese R, Farruggia P, et
al. long-term follow-up analysis after rituximab therapy in children with

refractory symptomatic ITP: identification of factors predictive of a sustained
response. Br J Haematol 2009; 144:552.
29. Bussel JB, Buchanan gR, nugent DJ, gnarra DJ, Bomgaars lR, Blanch-
ette Vs, et al. a randomized, double-blind study of romiplostim to deter-
mine its safety and efficacy in children with immune thrombocytopenia.
Blood 2011;118:28.